Astellas, Sanofi, Lundbeck up for innovation award; Lilly launches online molecule board game;

> Astellas' Dificlir, Sanofi's ($SNY) Lemtrada and Lundbeck's Selincro are a few of the contenders up for the 2014 Innovative Drug Award. Report

> IMS Health has announced it intends to acquire certain Cegedim information solutions and Customer Relationship Management businesses for €385 million ($520 million) in cash. Release

> Forest Laboratories' ($FRX) Viibryd performed significantly better than a placebo for treating generalized anxiety disorder, three late-stage studies show. Report

> Alexion ($AXLN) and Cincinnati Children's Hospital Medical Center have announced the establishment of a collaboration and fund for the advancement of research in rare disease. Release

> A University of Tokyo investigation panel found 'serious faults' in a Novartis ($NVS) significant input of company employees in the trial's planning stages. More

And Finally... Eli Lilly's ($LLY) new online board game, "Destination Discovery," helps users experience the challenges of "bringing a new medicine from molecule to medicine cabinet." More

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

Merck CEO Ken Frazier has spoken passionately about racism before. Monday, amid protests over George Floyd's death, he made that passion personal.

BMS is pricing Zeposia at the wholesale acquisition cost of $86,000, lower than the tag on Novartis' in-class rival Mayzent.